Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1

Bortezomib (Velcade) is used widely for the treatment of various human cancers; however, its mechanisms of action are not fully understood, particularly in myeloid malignancies. Bortezomib is a selective and reversible inhibitor of the proteasome. Paradoxically, we find that bortezomib induces prote...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Fang, Jing, Rhyasen, Garrett, Bolanos, Lyndsey, Rasch, Christopher, Varney, Melinda, Wunderlich, Mark, Goyama, Susumu, Jansen, Gerrit, Cloos, Jacqueline, Rigolino, Carmela, Cortelezzi, Agostino, Mulloy, James C., Oliva, Esther N., Cuzzola, Maria, Starczynowski, Daniel T.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2012
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3412348/
https://ncbi.nlm.nih.gov/pubmed/22685174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-02-407999
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars